Background
Background Antipsychotic drugs are Antipsychotic drugs are associated with adverse effects that can associated with adverse effects that can lead to poor medication adherence, lead to poor medication adherence, stigma, distress andimpaired qualityof life. stigma, distress andimpaired qualityof life.
Aims Aims To review the use of adverse
To review the use of adverse effects of antipsychotic drugs as outcome effects of antipsychotic drugs as outcome measures, with a particular emphasis on measures, with a particular emphasis on methodological issues. methodological issues.
Method Method Review of data on adverse
Review of data on adverse effects from sources including randomised effects from sources including randomised controlled trials (RCTs), post-marketing controlled trials (RCTs), post-marketing surveillance and naturalistic studies. surveillance and naturalistic studies.
Results

Results All have advantages and
All have advantages and disadvantages and the best overview disadvantages and the best overview comes from considering all sources of data comes from considering all sources of data together. Adverse effects are together. Adverse effects are inconsistently reported, hampering crossinconsistently reported, hampering crossstudy comparisons.Many outcome study comparisons.Many outcome measures lackclinical meaning.In both measures lackclinical meaning.In both naturalistic studies and RCTs adverse naturalistic studies and RCTs adverse effects often account for less treatment effects often account for less treatment discontinuation than lackof efficacy. discontinuation than lack of efficacy.
Conclusions Conclusions Standardisation in the
Standardisation in the reporting of adverse effects is needed. reporting of adverse effects is needed. Patients'subjective experience of Patients'subjective experience of medication should be given more medication should be given more consideration.Total discontinuation rates consideration.Total discontinuation rates provide a useful global outcome measure provide a useful global outcome measure that incorporates tolerability and efficacy that incorporates tolerability and efficacy as well as patient and clinician viewpoints. as well as patient and clinician viewpoints. Patients should be informed of common Patients should be informed of common side-effects prior to treatment and side-effects prior to treatment and monitored for their occurrence during monitored for their occurrence during treatment. treatment.
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Knowledge of how the prevalence and Knowledge of how the prevalence and severity of adverse effects vary for different severity of adverse effects vary for different antipsychotics allows clinicians to reduce antipsychotics allows clinicians to reduce the occurrence of these effects. We review the occurrence of these effects. We review the range of adverse effects associated with the range of adverse effects associated with antipsychotics and their clinical impact, antipsychotics and their clinical impact, and give an overview of the various sources and give an overview of the various sources of data on adverse effects and their relative of data on adverse effects and their relative strengths and weaknesses. Potential prostrengths and weaknesses. Potential problems in interpreting the evidence base are blems in interpreting the evidence base are considered and the importance of the considered and the importance of the patients' perspective emphasised. We patients' perspective emphasised. We conclude with an examination of total conclude with an examination of total discontinuation rates as a global measure discontinuation rates as a global measure of effectiveness that incorporates both of effectiveness that incorporates both tolerability and efficacy. tolerability and efficacy.
R ANGE AND CLINICAL RANGE AND CLINICAL IMPACT OF ADVERSE EFFECTS IMPACT OF ADVERSE EFFECTS
Antipsychotics are associated with a wide Antipsychotics are associated with a wide range of potential adverse effects (Appenrange of potential adverse effects (Appendix 1) which can affect the patient in dix 1) which can affect the patient in several ways (Fig. 1) . For example the several ways (Fig. 1) . For example the stiffness, slowness of movement and tremor stiffness, slowness of movement and tremor of antipsychotic-induced parkinsonism of antipsychotic-induced parkinsonism (Dursun (Dursun et al et al, 2004 ) can make it difficult , 2004) can make it difficult for a patient to write, fasten buttons and for a patient to write, fasten buttons and tie shoelaces, leading to reduced quality of tie shoelaces, leading to reduced quality of life. The blank 'mask-like' expression, life. The blank 'mask-like' expression, tremor, stooped posture, drooling and abtremor, stooped posture, drooling and abnormalities of gait (including lack of arm normalities of gait (including lack of arm swing) are easily observable by others and swing) are easily observable by others and mark the patient out as 'different', hence mark the patient out as 'different', hence contributing to stigma. When severe the contributing to stigma. When severe the festinant gait may result in falls and injury, festinant gait may result in falls and injury, particularly hip fracture in older patients. particularly hip fracture in older patients. Patients who recognise the link between Patients who recognise the link between these problems and antipsychotic medithese problems and antipsychotic medication may miss out doses or stop medication may miss out doses or stop medication totally. cation totally.
Many patients who adhere poorly to Many patients who adhere poorly to medication do not inform their clinical medication do not inform their clinical team of this and some go to great lengths team of this and some go to great lengths to hide their non-adherence (covert nonto hide their non-adherence (covert nonadherence). Poor adherence during acute adherence). Poor adherence during acute treatment of psychosis leads to chronic treatment of psychosis leads to chronic symptoms whereas poor adherence after resymptoms whereas poor adherence after remission increases the risk of relapse. Both mission increases the risk of relapse. Both may have serious consequences, including may have serious consequences, including self-harm, aggression and readmission to self-harm, aggression and readmission to hospital. When clinician and patient are hospital. When clinician and patient are aware of adverse effects, treatment can be aware of adverse effects, treatment can be adjusted to minimise the problems (e.g. adjusted to minimise the problems (e.g. dose reduction of the antipsychotic, predose reduction of the antipsychotic, prescription of an anti-Parkinsonian agent or scription of an anti-Parkinsonian agent or a switch to an alternative antipsychotic a switch to an alternative antipsychotic with less propensity to cause the adverse with less propensity to cause the adverse effect). effect).
SOURCES OF DATA SOURCES OF DATA
Data on adverse effects are available from a Data on adverse effects are available from a range of sources. These include randomised range of sources. These include randomised controlled trials (RCTs), naturalistic stucontrolled trials (RCTs), naturalistic studies, part-marketing surveillance, and nondies, part-marketing surveillance, and nonrandomised and open trials. Open and randomised and open trials. Open and non-randomised trials are methodologically non-randomised trials are methodologically inferior to double-blind randomised coninferior to double-blind randomised controlled trials but nevertheless contribute to trolled trials but nevertheless contribute to the evidence base. All data sources can be the evidence base. All data sources can be considered as being pieces of a jigsaw; the considered as being pieces of a jigsaw; the full picture of drug tolerability is only evifull picture of drug tolerability is only evident when all the pieces are put together. dent when all the pieces are put together.
Randomised controlled trials Randomised controlled trials
Strengths Strengths
Double-blind randomised trials are regarDouble-blind randomised trials are regarded as the gold standard level of evidence ded as the gold standard level of evidence for the following reasons. for the following reasons.
(a) (a) Randomisation reduces the risk of bias Randomisation reduces the risk of bias in baseline characteristics and so in baseline characteristics and so makes it more probable that differences makes it more probable that differences in outcome reflect differences between in outcome reflect differences between the treatments being investigated. the treatments being investigated. In practice these advantages are not In practice these advantages are not always as clear-cut as they seem. For examalways as clear-cut as they seem. For example, relatively few trials assess the success of ple, relatively few trials assess the success of masking and when they do the methods masking and when they do the methods s 6 4 s 6 4 B R I T I S H J O UR N A L O F P S YC H I AT RY B R I T I S H J O UR N A L O F P SYC H I AT RY ( 2 0 0 7 ) , 1 9 1 ( s u p p l . 5 0 ) , s 6 4^s 7 0 . d o i : 1 0 .11 9 2 / b j p .1 9 1 . 5 0 . s 6 4 ( 2 0 0 7 ) , 1 9 1 ( s u p p l . 5 0 ) , s 6 4^s 7 0 . d o i : 1 0 .11 9 2 / b j p .1 9 1 . 5 0 . American Journal of Psychiatry, , showed that reporting of the method of showed that reporting of the method of randomisation was uncommon (Ogundipe randomisation was uncommon (Ogundipe et al et al, 1999) . The authors concluded that , 1999). The authors concluded that the RCT status of some of the papers must the RCT status of some of the papers must therefore be in doubt. therefore be in doubt.
Weaknesses Weaknesses
Although RCTs can allow accurate inforAlthough RCTs can allow accurate information on the incidence and prevalence of mation on the incidence and prevalence of adverse effects to be gathered, most trials adverse effects to be gathered, most trials of antipsychotics have relatively small of antipsychotics have relatively small samples and are short term, lasting 4-8 samples and are short term, lasting 4-8 weeks. Such studies may underestimate weeks. Such studies may underestimate early-onset side-effects that are uncommon early-onset side-effects that are uncommon and cannot provide data on side-effects that and cannot provide data on side-effects that develop in the medium and long term. For develop in the medium and long term. For example, amenorrhoea is an adverse effect example, amenorrhoea is an adverse effect of antipsychotics that reflects hyperprolacof antipsychotics that reflects hyperprolactinaemia (Wieck & Haddad, 2003) . In the tinaemia (Wieck & Haddad, 2003) . In the Schizophrenia Outpatient Health Outcome Schizophrenia Outpatient Health Outcome (SOHO) study the baseline prevalence was (SOHO) study the baseline prevalence was approximately 33% of women (Haro & approximately 33% of women (Haro & Salvador-Carulla, 2006) . Definitions of Salvador-Carulla, 2006) . Definitions of amenorrhoea differ; if it is defined as three amenorrhoea differ; if it is defined as three consecutive missed episodes of menstruation consecutive missed episodes of menstruation then it will be impossible to detect in a drug then it will be impossible to detect in a drug trial of less than 12 weeks' duration. The trial of less than 12 weeks' duration. The inability of short-term trials to provide data inability of short-term trials to provide data on long-term tolerability, including weight on long-term tolerability, including weight gain, sexual functioning and metabolic gain, sexual functioning and metabolic parameters, is a major weakness, as in parameters, is a major weakness, as in clinical practice antipsychotics are often clinical practice antipsychotics are often prescribed to patients for several years or prescribed to patients for several years or even decades. This drawback has been even decades. This drawback has been partly addressed by two recently published partly addressed by two recently published RCTs with relatively long follow-up periods: RCTs with relatively long follow-up periods: the Cost-Utility of the Latest Antipsychotic the Cost-Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS) 
Naturalistic studies Naturalistic studies
Naturalistic studies, including pharmacoNaturalistic studies, including pharmacoepidemiological studies, have the advantage epidemiological studies, have the advantage of assessing 'real world' patients. Pharmacoof assessing 'real world' patients. Pharmacoepidemiological studies can have very large epidemiological studies can have very large samples, enabling relatively rare adverse samples, enabling relatively rare adverse effects to be investigated. Both incidence effects to be investigated. Both incidence and prevalence data can be generated. and prevalence data can be generated. These studies are limited to data recorded These studies are limited to data recorded on computerised record systems and the on computerised record systems and the absence of relevant data may prevent absence of relevant data may prevent adjustment for potential confounding fac adjustment for potential confounding factors. tors. Furthermore, the lack of randomisation limits Furthermore, the lack of randomisation limits attribution of causality. Data regarding the attribution of causality. Data regarding the safety of drugs in pregnancy derive from safety of drugs in pregnancy derive from post-marketing surveillance and naturalispost-marketing surveillance and naturalistic studies because pregnant women are tic studies because pregnant women are invariably excluded from RCTs. invariably excluded from RCTs.
Post-marketing surveillance Post-marketing surveillance Post-marketing surveillance is an essential Post-marketing surveillance is an essential component of assessing drug safety and component of assessing drug safety and s 6 5 s 6 5 AUTHOR'S PROOF AUTHOR'S PROOF tolerability, and often provides the first tolerability, and often provides the first evidence of adverse effects that are rare or evidence of adverse effects that are rare or confined to particular at-risk groups. confined to particular at-risk groups.
Remoxipride was an antipsychotic marRemoxipride was an antipsychotic marketed in the late 1980s. Trials indicated keted in the late 1980s. Trials indicated similar efficacy to haloperidol for treating similar efficacy to haloperidol for treating positive and negative symptoms but with positive and negative symptoms but with less risk of extrapyramidal side-effects. Folless risk of extrapyramidal side-effects. Following its introduction in Europe a signifilowing its introduction in Europe a significant number of cases of aplastic anaemia cant number of cases of aplastic anaemia were reported (as many as 1 in 10 000). were reported (as many as 1 in 10 000).
Remoxipride was withdrawn in 1993 (Fung Remoxipride was withdrawn in 1993 (Fung et al et al, 2001) . Pimozide is a conventional , 2001). Pimozide is a conventional antipsychotic. Between 1971 and 1995 , 16 antipsychotic. Between 1971 and 1995 deaths and 24 cases of serious cardiac deaths and 24 cases of serious cardiac events were reported to the Committee for events were reported to the Committee for the Safety of Medicines. This led to the the Safety of Medicines. This led to the following recommendations: (a) patients following recommendations: (a) patients prescribed pimozide should undergo a baseprescribed pimozide should undergo a baseline electrocardiogram (ECG) followed by line electrocardiogram (ECG) followed by annual ECGs; (b) if the QTc interval is proannual ECGs; (b) if the QTc interval is prolonged, treatment needs to be closely superlonged, treatment needs to be closely supervised or withdrawn; and (c) pimozide vised or withdrawn; and (c) pimozide should not be prescribed in conjunction should not be prescribed in conjunction with other drugs that prolong the QTc inwith other drugs that prolong the QTc interval . terval .
Post-marketing surveillance includes Post-marketing surveillance includes prescription event monitoring (Mann, prescription event monitoring (Mann, 1998) and reports of adverse drug reactions 1998) and reports of adverse drug reactions (Gough, 2005) . Various national and inter- (Gough, 2005) . Various national and international regulatory bodies provide systems national regulatory bodies provide systems for post-marketing surveillance, an example for post-marketing surveillance, an example being the UK yellow card system for reportbeing the UK yellow card system for reporting adverse drug reactions. Post-marketing ing adverse drug reactions. Post-marketing surveillance is also conducted by pharmasurveillance is also conducted by pharmaceutical companies or by independent receutical companies or by independent research companies employed by them. The search companies employed by them. The potential conflict of interest inherent in potential conflict of interest inherent in manufacturers collecting, evaluating and manufacturers collecting, evaluating and reporting post-marketing data on their reporting post-marketing data on their own products has been the subject of recent own products has been the subject of recent discussion (Fontanarosa discussion (Fontanarosa et al et al, 2004 ). This , 2004 . This point apart, post-marketing surveillance point apart, post-marketing surveillance has several weaknesses: it relies on volunhas several weaknesses: it relies on voluntary participation; underreporting is widetary participation; underreporting is widespread; submitted reports may be of poor spread; submitted reports may be of poor quality with inadequate detail; and the quality with inadequate detail; and the ability to confirm causality is limited. ability to confirm causality is limited. Incomplete numerator data on events and Incomplete numerator data on events and unreliable denominator data make it diffiunreliable denominator data make it difficult to calculate rates of adverse events. cult to calculate rates of adverse events.
The withdrawal of drugs for safety reaThe withdrawal of drugs for safety reasons demonstrates that licensing is not a sons demonstrates that licensing is not a guarantee of safety and highlights the imguarantee of safety and highlights the importance of the continuing assessment of portance of the continuing assessment of tolerability and safety from further studies tolerability and safety from further studies and post-marketing surveillance. Between and post-marketing surveillance. Between 1960 and 1999 121 prescription drugs were 1960 and 1999 121 prescription drugs were withdrawn from worldwide markets for withdrawn from worldwide markets for safety reasons (Fung safety reasons (Fung et al et al, 2001) . Drugs , 2001 ). Drugs that act on the central nervous system were that act on the central nervous system were the most common category withdrawn; in a the most common category withdrawn; in a more detailed breakdown by drug class more detailed breakdown by drug class antidepressants were ranked fifth (7.4%). antidepressants were ranked fifth (7.4%). 
Drug carry-over effects Drug carry-over effects
A second problem is that most trials A second problem is that most trials evaluate patients with chronic psychosis evaluate patients with chronic psychosis who must discontinue a previous antiwho must discontinue a previous antipsychotic before starting the trial. This psychotic before starting the trial. This makes drug carry-over effects inevitable. makes drug carry-over effects inevitable. For example, the potential for weight gain For example, the potential for weight gain associated with a particular antipsychotic associated with a particular antipsychotic is underestimated, as patients are likely to is underestimated, as patients are likely to have gained weight during previous antihave gained weight during previous antipsychotic treatment, thus minimising their psychotic treatment, thus minimising their potential for further weight gain (Haddad, potential for further weight gain (Haddad, 2005) . Assessing patients with first-onset 2005). Assessing patients with first-onset psychosis who are drug naive overcomes psychosis who are drug naive overcomes this problem, but enrolling such patients this problem, but enrolling such patients into trials is notoriously difficult and such into trials is notoriously difficult and such RCTs are rare. RCTs are rare.
Bias in trial design Bias in trial design
Industry-sponsored trials are more likely to Industry-sponsored trials are more likely to report results that favour the sponsor's report results that favour the sponsor's compound than are independent studies compound than are independent studies (Ahmer (Ahmer et al et al, 2005) . Possible explanations , 2005). Possible explanations include publication bias and bias in trial deinclude publication bias and bias in trial design. An example of the latter is that most sign. An example of the latter is that most RCTs of atypical antipsychotics employ RCTs of atypical antipsychotics employ haloperidol as the active comparator. haloperidol as the active comparator. Among Among the conventional antipsychotics, the conventional antipsychotics, haloperidol haloperidol is associated with a high inciis associated with a high incidence of extrapyramidal side-effects (EPS) dence of extrapyramidal side-effects (EPS) and so it is not surprising that these studies and so it is not surprising that these studies generally report an advantage in relation to generally report an advantage in relation to EPS for the atypical agents, an advantage EPS for the atypical agents, an advantage that re that remains in meta-analyses (Geddes mains in meta-analyses (Geddes et  et 
Comparison between trials Comparison between trials
It is often necessary to compare data on adIt is often necessary to compare data on adverse effects between trials. For example, verse effects between trials. For example, the relatively few head-to-head RCTs of the relatively few head-to-head RCTs of atypical antipsychotics make cross-study atypical antipsychotics make cross-study comparisons, despite their methodological comparisons, despite their methodological pitfalls, a necessity. Furthermore, as estipitfalls, a necessity. Furthermore, as estimates of the prevalence/severity of an admates of the prevalence/severity of an adverse effect for any given drug will vary verse effect for any given drug will vary between trials, an adjusted value is often rebetween trials, an adjusted value is often required. Meta-analysis is commonly used to quired. Meta-analysis is commonly used to allow data from different studies to be allow data from different studies to be pooled and compared, but this approach pooled and compared, but this approach is often not possible when analysing data is often not possible when analysing data on adverse effects because of varying methon adverse effects because of varying methodologies used to assess such effects. For odologies used to assess such effects. For example, there are several scales to measure example, there are several scales to measure sexual function (Table 1) . Parkinsonian sexual function (Table 1) . Parkinsonian symptoms are usually assessed using the symptoms are usually assessed using the Simpson-Angus Scale (Simpson & Angus, Simpson-Angus Scale (Simpson & Angus, 1970) , but some studies report the propor-1970), but some studies report the proportion of patients prescribed an anticholingeric tion of patients prescribed an anticholingeric drug, a clinical proxy for parkinsonism. Even drug, a clinical proxy for parkinsonism. Even when the same rating scale or measure is when the same rating scale or measure is used, the outcome may used, the outcome may be expressed in difbe expressed in different ways. Parkinsonian ferent ways. Parkinsonian symptoms may symptoms may be reported as mean change in score on be reported as mean change in score on the Simpson-Angus Scale from baseline to the Simpson-Angus Scale from baseline to end-point or as the number of patients with end-point or as the number of patients with scores above a specified cut-off. Similarly, scores above a specified cut-off. Similarly, measures of weight change during a study measures of weight change during a study include mean change in kilograms, the include mean change in kilograms, the percentage of patients with increments of percentage of patients with increments of weight change (e.g. 0-5 kg, 5-10 kg, etc.) weight change (e.g. 0-5 kg, 5-10 kg, etc.) and the number of patients with an arbiand the number of patients with an arbitrary measure of significant weight gain, trary measure of significant weight gain, (e.g. an increase of more than 7% of base-(e.g. an increase of more than 7% of baseline weight). line weight).
Outcome measures Outcome measures that lack clinical utility that lack clinical utility
Many studies present data on adverse effects Many studies present data on adverse effects in terms of the mean change in an outcome in terms of the mean change in an outcome measure (e.g. a rating scale or the blood measure (e.g. a rating scale or the blood s 6 6 s 6 6 concentration of a compound). Often this concentration of a compound). Often this has no clinical utility to the clinician or has no clinical utility to the clinician or patient. For example, reporting the mean patient. For example, reporting the mean change in serum prolactin during the course change in serum prolactin during the course of a trial is far less relevant than reporting of a trial is far less relevant than reporting the proportion of patients with a prolactin the proportion of patients with a prolactin level above the upper limit of normal at level above the upper limit of normal at the start and end of the study. Even more the start and end of the study. Even more useful is the proportion of these patients useful is the proportion of these patients who also have symptoms consistent with who also have symptoms consistent with hyperprolactinaemia (i.e. the proportion hyperprolactinaemia (i.e. the proportion with biochemical plus clinical hyperprolacwith biochemical plus clinical hyperprolactinaemia). Similarly, mean weight change is tinaemia). Similarly, mean weight change is less useful than knowing the proportion of less useful than knowing the proportion of patients with specific increments of weight patients with specific increments of weight change. change.
Comparing like with like Comparing like with like
When trial data are reviewed to aid the When trial data are reviewed to aid the treatment of a specific patient (e.g. to assist treatment of a specific patient (e.g. to assist selection of an antipsychotic drug), it is selection of an antipsychotic drug), it is important to ensure that the trials reviewed important to ensure that the trials reviewed deal with patients with similar characterisdeal with patients with similar characteristics to the patient being treated and use tics to the patient being treated and use similar drug dosages to those likely to be similar drug dosages to those likely to be used clinically. For example, used clinically. For example, data on addata on adverse effects gathered from trials in patients verse effects gathered from trials in patients with chronic schizophrenia cannot be reliwith chronic schizophrenia cannot be reliably applied to drug-naive patients, as the ably applied to drug-naive patients, as the latter are more sensitive to a range of latter are more sensitive to a range of adverse effects. Similarly, premenopausal adverse effects. Similarly, premenopausal women are more prone to develop antiwomen are more prone to develop antipsychotic-induced hyperprolactinaemia than psychotic-induced hyperprolactinaemia than postmenopausal women. Consequently it postmenopausal women. Consequently it would be misleading to extrapolate data would be misleading to extrapolate data on prolactin-related side-effects from an on prolactin-related side-effects from an RCT that included a high proportion of RCT that included a high proportion of postmenopausal women to the treatment postmenopausal women to the treatment of a premenopausal patient. When trials of a premenopausal patient. When trials are combined in a meta-analysis one should are combined in a meta-analysis one should consider whether differences between the consider whether differences between the trials in terms of populations studied, drug trials in terms of populations studied, drug dosage and the duration of treatment invadosage and the duration of treatment invalidate the approach. Most adverse effects lidate the approach. Most adverse effects are dose related but the relationship beare dose related but the relationship between the prevalence of an adverse effect tween the prevalence of an adverse effect and duration of drug treatment varies deand duration of drug treatment varies depending on the effect being considered. pending on the effect being considered. For example, akathisia is particularly comFor example, akathisia is particularly common in the first week after starting an antimon in the first week after starting an antipsychotic or increasing the dose whereas psychotic or increasing the dose whereas tardive dyskinesia usually only appears tardive dyskinesia usually only appears after several months or years of treatment after several months or years of treatment (Dursun (Dursun et al et al, 2004) . , 2004). ). Other reasons for dissatisfaction include lack of involvefor dissatisfaction include lack of involvement in treatment planning or decisionment in treatment planning or decisionmaking, lack of involvement with treatmaking, lack of involvement with treatment options, drug side-effects and lack of ment options, drug side-effects and lack of information about these. In a UK survey information about these. In a UK survey of callers to a national mental health teleof callers to a national mental health telephone helpline, distressing side-effects were phone helpline, distressing side-effects were strongly correlated with low treatment strongly correlated with low treatment satisfaction (Fakhoury satisfaction (Fakhoury et al et al, 2001) . In this , 2001). In this survey the most distressing side-effects survey the most distressing side-effects reported (percentage of patients with the reported (percentage of patients with the side-effect who reported it as distressing) side-effect who reported it as distressing) were weight gain (73%), depression were weight gain (73%), depression (67%), insomnia (66%), difficulty think-(67%), insomnia (66%), difficulty thinking/concentrating (63%), sedation (59%) ing/concentrating (63%), sedation (59%) and sexual dysfunction (58%). Men were and sexual dysfunction (58%). Men were more likely to report sexual dysfunction more likely to report sexual dysfunction as distressing and women more likely to as distressing and women more likely to report weight gain as distressing. Several report weight gain as distressing. Several studies indicate that adverse effects of antistudies indicate that adverse effects of antipsychotics are often not diagnosed or treapsychotics are often not diagnosed or treated (e.g. Mitra & Haddad, 2007) and that ted (e.g. Mitra & Haddad, 2007) and that psychiatrists tend to underestimate the dispsychiatrists tend to underestimate the distress that they cause (e.g. Day tress that they cause (e.g. Day et al et al, 1998) . , 1998).
PATIENT PERSPECTIVE PATIENT PERSPECTIVE
Subjective quality of life Subjective quality of life
Many factors influence a patient's view of Many factors influence a patient's view of their quality of life, including positive and their quality of life, including positive and negative symptoms, depression, cognitive negative symptoms, depression, cognitive impairment, hospitalisation and perceived impairment, hospitalisation and perceived support (Thornicroft support (Thornicroft et al et al, 2004 ). Several , 2004 . Several studies have reported that quality of life is studies have reported that quality of life is higher in patients treated with atypical higher in patients treated with atypical antipsychotics than in those treated with antipsychotics than in those treated with conventional antipsychotics (Franz conventional antipsychotics (Franz et al et al, , 1997) . However, in the CATIE study, the 1997). However, in the CATIE study, the largest independent randomised doublelargest independent randomised doubleblind study in schizophrenia research, there blind study in schizophrenia research, there were no significant differences in psychosowere no significant differences in psychosocial functioning (assessed using the Quality cial functioning (assessed using the Quality of Life Scale; Heinrichs of Life Scale; Heinrichs et al et al, 1984 Heinrichs et al et al, ) be-, 1984 between those treated with atypical drugs tween those treated with atypical drugs and those treated with perphenazine, a and those treated with perphenazine, a conventional drug; all treatment groups conventional drug; all treatment groups showed modest improvement (Swartz showed modest improvement (Swartz et et al al, 2007) . This is consistent with the , 2007). This is consistent with the CUtLASS study (Jones CUtLASS study (Jones et al et al, 2006 (Jones et al et al, ), which , 2006 , which found no difference in quality of life scores found no difference in quality of life scores between patients prescribed typical and between patients prescribed typical and atypical antipsychotics. atypical antipsychotics.
Subjective response to treatment Subjective response to treatment
The Drug Attitude Inventory (DAI; Hogan The Drug Attitude Inventory (DAI; Hogan et al et al, 1983 ) is an established tool that as-, 1983) is an established tool that assesses acceptability and subjective tolerabilsesses acceptability and subjective tolerability (subjective response) of medication. ity (subjective response) of medication. Factors that influence subjective response Factors that influence subjective response include insight, previous experience of include insight, previous experience of medication, health beliefs and the quality medication, health beliefs and the quality of the therapeutic relationship. In one study of the therapeutic relationship. In one study patients on atypical antipsychotics reported patients on atypical antipsychotics reported a more positive subjective response and a a more positive subjective response and a lower prevalence of dysphoria than those lower prevalence of dysphoria than those on typical antipsychotics (Voruganti on typical antipsychotics (Voruganti et al et al, , 2000) . Subjective response, as assessed by 2000). Subjective response, as assessed by DAI score, is strongly correlated with ad-DAI score, is strongly correlated with adherence (Awad & Hogan, 1994) . However, herence (Awad & Hogan, 1994) . However, adherence is influenced by many other facadherence is influenced by many other factors, including the quality of the therapeutic tors, including the quality of the therapeutic relationship between the patient and physirelationship between the patient and physician or keyworker (Frank & Gunderson, cian or keyworker (Frank & Gunderson, 1990 1990 ). ).
DISCONTINUATIONS DISCONTINUATIONS OWING TO INTOLER ABILITY OWING TO INTOLER ABILITY
When interpreting trials there is often a tenWhen interpreting trials there is often a tendency to consider individual side-effects in dency to consider individual side-effects in isolation (e.g. weight gain, EPS, hyperisolation (e.g. weight gain, EPS, hyperprolactinaemia, etc.) In reality patients ofprolactinaemia, etc.) In reality patients often experience several adverse effects, and ten experience several adverse effects, and whereas each on its own may be minor towhereas each on its own may be minor together they may be a major burden. One gether they may be a major burden. One measure of overall tolerability is the promeasure of overall tolerability is the proportion of patients who stop treatment portion of patients who stop treatment and cite side-effects as the cause. Although and cite side-effects as the cause. Although intolerability is a major cause of antiintolerability is a major cause of antipsychotic drug discontinuation in schizopsychotic drug discontinuation in schizophrenia it often accounts for fewer phrenia it often accounts for fewer discontinuations than lack of efficacy discontinuations than lack of efficacy (Lieberman (Lieberman et al et al, 2005; Kinon , 2005; Kinon et al et al, 2006; , 2006; Haro Haro et al et al, 2007) . For example in phase I , 2007). For example in phase I of the CATIE study patients were randomof the CATIE study patients were randomised double-blind to one of five antiised double-blind to one of five antipsychotics and followed for up to 18 psychotics and followed for up to 18 months. In four of the five drug cohorts more months. In four of the five drug cohorts more patients stopped treatment for lack of effipatients stopped treatment for lack of efficacy than for intolerability cacy than for intolerability (Lieberman (Lieberman et et al al, 2005 ; Fig. 2 ). In the naturalistic SOHO , 2005; Fig. 2 ). In the naturalistic SOHO study the percentage of patients discontinustudy the percentage of patients discontinuing treatment over 3 years because of lack ing treatment over 3 years because of lack of efficacy exceeded those discontinuing of efficacy exceeded those discontinuing treatment for intolerability in all drug treatment for intolerability in all drug cohorts (Haro cohorts (Haro et al et al, 2007) . This was also , 2007). This was also the case in a meta-analysis of four the case in a meta-analysis of four RCTs RCTs of olanzapine in schizophrenia (Kinon of olanzapine in schizophrenia (Kinon et al et al, , 2006 (Kinon et al et al, , ). 2006 .
These results are consistent with a These results are consistent with a concept mapping study that investigated concept mapping study that investigated medication adherence in people with medication adherence in people with schizophrenia (Kikkert schizophrenia (Kikkert et al et al, 2006) . Based , 2006) . Based on interviews with people with schizoon interviews with people with schizophrenia, carers and health professionals, phrenia, carers and health professionals, ten clinically relevant clusters were identiten clinically relevant clusters were identified that affected medication adherence. fied that affected medication adherence. Medication efficacy was rated by patients Medication efficacy was rated by patients and carers as the most important cluster afand carers as the most important cluster affecting adherence, but professionals rated fecting adherence, but professionals rated this as significantly less important, ranking this as significantly less important, ranking it fifth out of the ten clusters. Conversely it fifth out of the ten clusters. Conversely patients and carers placed side-effects relapatients and carers placed side-effects relatively low compared with positive aspects tively low compared with positive aspects of medication, whereas professionals of medication, whereas professionals prioritised side-effects as the second most prioritised side-effects as the second most important cluster. So, compared with important cluster. So, compared with patients and carers, professionals overpatients and carers, professionals overestimate the importance of adverse effects estimate the importance of adverse effects for adherence and underestimate the for adherence and underestimate the importance of efficacy. importance of efficacy.
TOTAL DISCONTINUATION TOTAL DISCONTINUATION RATES : GLOBAL MEASURE R ATES : GLOBAL MEASURE OF EFFECTIVENESS OF EFFECTIVENESS
Clinicians and patients need to balance adClinicians and patients need to balance adverse effects against the effectiveness of a verse effects against the effectiveness of a drug in treating the psychiatric illness. If a drug in treating the psychiatric illness. If a patient obtains significant benefit from a patient obtains significant benefit from a drug they may be willing to put up with drug they may be willing to put up with considerable adverse effects (as demonconsiderable adverse effects (as demonstrated with clozapine). Adverse effects strated with clozapine). Adverse effects are common with clozapine and regular are common with clozapine and regular monitoring of the full blood count is manmonitoring of the full blood count is mandatory throughout treatment, owing to the datory throughout treatment, owing to the risk of neutropaenia. Nevertheless patients risk of neutropaenia. Nevertheless patients often accept the adverse effects, presumably often accept the adverse effects, presumably because clozapine provides a level of sympbecause clozapine provides a level of symptom control for their treatment-resistant illtom control for their treatment-resistant illness that was not achieved with previous ness that was not achieved with previous antipsychotics. In problem-centred interantipsychotics. In problem-centred interviews with patients discharged from hospiviews with patients discharged from hospital on clozapine a wide range of side-effects tal on clozapine a wide range of side-effects were reported, including fatigue or sedation were reported, including fatigue or sedation (56%), lack of motivation (21%), hyper-(56%), lack of motivation (21%), hypersalivation (21%), anticholinergic effects salivation (21%), anticholinergic effects (16%), weight gain (15%) and orthostatic (16%), weight gain (15%) and orthostatic hypotension (11%) (Angermeyer hypotension (11%) (Angermeyer et al et al, , 2001) . Despite this nearly one-third of 2001). Despite this nearly one-third of patients stated that they felt better as a repatients stated that they felt better as a result of clozapine and almost half expected sult of clozapine and almost half expected a worsening of their mental state if they a worsening of their mental state if they stopped the medication. stopped the medication.
Thus it is helpful to have a global meaThus it is helpful to have a global measure of the effectiveness of a drug that comsure of the effectiveness of a drug that combines both tolerability and effectiveness in bines both tolerability and effectiveness in treating symptoms. One way to achieve this treating symptoms. One way to achieve this is to record the total discontinuation rate on is to record the total discontinuation rate on the drug at a given time point or the time to the drug at a given time point or the time to discontinuation for any reason. As stopping discontinuation for any reason. As stopping medication in a trial is a joint decision made medication in a trial is a joint decision made by patient and clinician, this outcome meaby patient and clinician, this outcome measure also has the advantage of incorporating sure also has the advantage of incorporating the patient's and the clinician's views. the patient's and the clinician's views.
Discontinuation of treatment for any Discontinuation of treatment for any reason was the primary outcome measure reason was the primary outcome measure in the CATIE study (Lieberman in the CATIE study (Lieberman et al et al, , 2005) . The results of phase I of the study 2005). The results of phase I of the study illustrate the importance of balancing effiillustrate the importance of balancing efficacy and tolerability. Of the five anticacy and tolerability. Of the five antipsychotics in phase I, olanzapine was psychotics in phase I, olanzapine was associated with the highest percentage of associated with the highest percentage of patients stopping treatment because of patients stopping treatment because of intolerability but the lowest percentage intolerability but the lowest percentage stopping treatment for lack of efficacy stopping treatment for lack of efficacy (Leiberman (Leiberman et al et al, 2005) . When discon-, 2005). When discontinuations owing to lack of efficacy and tinuations owing to lack of efficacy and intolerability were combined with discontiintolerability were combined with discontinuations for other reasons then the total nuations for other reasons then the total discontinuation rate for each of the five discontinuation rate for each of the five antipsychotics was lowest with olanzapine antipsychotics was lowest with olanzapine (Fig. 2) . The high total discontinuation (Fig. 2) . The high total discontinuation rates seen with all drugs in the CATIE study rates seen with all drugs in the CATIE study might partly reflect the double-blind design might partly reflect the double-blind design (Haddad & Dursun, 2006) . (Haddad & Dursun, 2006) .
The total discontinuation rate has also The total discontinuation rate has also been used as the outcome measure in been used as the outcome measure in several naturalistic studies (Hodgson several naturalistic studies (Hodgson et al et al, , 2005; Tiihonen 2005; Tiihonen et al et al, 2006) . Of particular , 2006) . Of particular note is the study by Tiihonen note is the study by Tiihonen et al et al (2006 Tiihonen et al et al ( ) (2006 in which a nationwide cohort of 2230 conin which a nationwide cohort of 2230 consecutive adults hospitalised in Finland for secutive adults hospitalised in Finland for the first time with a diagnosis of schizothe first time with a diagnosis of schizophrenia or schizoaffective disorder were phrenia or schizoaffective disorder were followed prospectively. Total rates of disfollowed prospectively. Total rates of discontinuation, adjusted for the effect of concontinuation, adjusted for the effect of confounders, were determined for the ten most founders, were determined for the ten most commonly used antipsychotics and comcommonly used antipsychotics and compared with haloperidol. Initial treatment pared with haloperidol. Initial treatment with clozapine, perphenazine depot and with clozapine, perphenazine depot and olanzapine were associated with the lowest olanzapine were associated with the lowest total discontinuation rates, and in all three total discontinuation rates, and in all three cases these were significantly less than the cases these were significantly less than the rate associated with haloperidol. Significant rate associated with haloperidol. Significant differences were also seen between antidifferences were also seen between antipsychotics in the rates of readmission, with psychotics in the rates of readmission, with clozapine, perphenazine depot and olanzaclozapine, perphenazine depot and olanzapine all being associated with significantly pine all being associated with significantly lower readmission rates than haloperidol. lower readmission rates than haloperidol.
CONCLUSIONS CONCLUSIONS
Data on adverse effects are available from a Data on adverse effects are available from a range of sources, including randomised range of sources, including randomised controlled trials, post-marketing surveilcontrolled trials, post-marketing surveillance and naturalistic studies. All sources lance and naturalistic studies. All sources of data carry their own advantages and disof data carry their own advantages and disadvantages. The best overview of adverse advantages. The best overview of adverse effects comes from considering all sources effects comes from considering all sources together. There is inconsistent reporting of together. There is inconsistent reporting of adverse effects across studies and many adverse effects across studies and many outcome measures lack clinical meaning. outcome measures lack clinical meaning. Future research would benefit greatly if Future research would benefit greatly if standardisation for the reporting of adverse standardisation for the reporting of adverse effects could be reached. The impact of effects could be reached. The impact of side-effects on patients has not been suffiside-effects on patients has not been sufficiently studied. It is important that the ciently studied. It is important that the patient's subjective experience, in which patient's subjective experience, in which adverse effects have a role, are considered adverse effects have a role, are considered in the assessment of a drug. Although adin the assessment of a drug. Although adverse effects are an important outcome, verse effects are an important outcome, with many antipsychotics they account for with many antipsychotics they account for less treatment discontinuation than lack of less treatment discontinuation than lack of efficacy; this finding has been noted in efficacy; this finding has been noted in naturalistic studies and in RCTs. Total naturalistic studies and in RCTs. Total s 6 8 s 6 8 AUTHOR'S PROOF AUTHOR'S PROOF 
